Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD

Blood

Volumn 127, Issue 5, 2016, Pages 646-657

  Alho, Ana C ^a,c   Kim, Haesook T ^d,e   Chammas, Marie J ^a   Reynolds, Carol G ^a   Matos, Tiago R ^a,b   Forcade, Edouard ^a,b   Whangbo, Jennifer ^a,b   Nikiforow, Sarah ^a,b   Cutler, Corey S ^a,b   Koreth, John ^a,b   Ho, Vincent T ^a,b   Armand, Philippe ^a,b   Antin, Joseph H ^a,b   Alyea, Edwin P ^a,b   Lacerda, Joao F ^c   Soiffer, Robert J ^a,b   Ritz, Jerome ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d Department of Biostatistics and Computational Biology ^*  (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FLUDARABINE; METHOTREXATE; MYCOPHENOLATE MOFETIL; PROTEIN BCL 2; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; EFFECTOR CELL; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPHENOTYPING; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; THYMOCYTE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84958191434     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-672345     Document Type: Article

References (47)

1. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: An update. Blood. 2010;115(19):3861-3868.
2. Kim DH, Sohn SK, Won DI, Lee NY, Suh JS, Lee KB. Rapid helper T-cell recovery above 200 x 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;37(12):1119-1128.
3. Storek J, Geddes M, Khan F, et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol. 2008;30(4):425-437.
4. Podgorny PJ, Liu Y, Dharmani-Khan P, et al. Immune cell subset counts associated with graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(4):450-462.
5. Mirmonsef P, Tan G, Zhou G, et al. Escape from suppression: Tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation. Blood. 2008;111(4):2112-2121.
6. Dong S, Maiella S, Xhaard A, et al. Multiparameter single-cell profiling of human CD41FOXP31 regulatory T-cell populations in homeostatic conditions and during graft-versushost disease. Blood. 2013;122(10):1802-1812.
7. Xhaard A, Moins-Teisserenc H, Busson M, et al. Reconstitution of regulatory T-cell subsets after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49(8):1089-1092.
8. Imanguli MM, Cowen EW, Rose J, et al. Comparative analysis of FoxP3(1) regulatory T cells in the target tissues and blood in chronic graft versus host disease. Leukemia. 2014;28(10):2016-2027.
9. Murase K, Kim HT, Bascug OR, et al. Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014; 99(9):1499-1508.
10. Yuan X, Cheng G, Malek TR. The importance of regulatory T-cell heterogeneity in maintaining selftolerance. Immunol Rev. 2014;259(1):103-114.
11. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531-564.
12. Edinger M, Hoffmann P, Ermann J, et al. CD41CD251 regulatory T cells preserve graftversus-Tumor activity while inhibiting graft-versushost disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150.
13. Miura Y, Thoburn CJ, Bright EC, et al. Association of Foxp3 regulatory gene expression with graftversus-host disease. Blood. 2004;104(7): 2187-2193.
14. Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP31 CD41CD251 regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005;106(8):2903-2911.
15. Bolton HA, Zhu E, Terry AM, et al. Selective Treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease. J Clin Invest. 2015;125(9):3627-3641.
16. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443-458.
17. Socíe G, Ritz J. Current issues in chronic graftversus-host disease. Blood. 2014;124(3): 374-384.
18. Grossman Z, Min B, Meier-Schellersheim M, Paul WE. Concomitant regulation of T-cell activation and homeostasis. Nat Rev Immunol. 2004;4(5): 387-395.
19. Boyman O, Ĺetourneau S, Krieg C, Sprent J. Homeostatic proliferation and survival of naive and memory T cells. Eur J Immunol. 2009;39(8): 2088-2094.
20. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity. 2008;29(6):848-862.
21. Liston A, Gray DH. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol. 2014;14(3):154-165.
22. Krenger W, Blazar BR, Holländer GA. Thymic T-cell development in allogeneic stem cell transplantation. Blood. 2011;117(25):6768-6776.
23. Boyman O, Purton JF, Surh CD, Sprent J. Cytokines and T-cell homeostasis. Curr Opin Immunol. 2007;19(3):320-326.
24. Takada K, Jameson SC. Naive T cell homeostasis: from awareness of space to a sense of place. Nat Rev Immunol. 2009;9(12):823-832.
25. Nguyen VH, Shashidhar S, Chang DS, et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood. 2008;111(2):945-953.
26. Matsuoka K, Kim HT, McDonough S, et al. Altered regulatory T cell homeostasis in patients with CD41 lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010;120(5):1479-1493.
27. Thome JJ, Yudanin N, Ohmura Y, et al. Spatial map of human T cell compartmentalization and maintenance over decades of life. Cell. 2014; 159(4):814-828.
28. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754): 708-712.
29. Surh CD, Boyman O, Purton JF, Sprent J. Homeostasis of memory T cells. Immunol Rev. 2006;211:154-163.
30. Junge S, Kloeckener-Gruissem B, Zufferey R, et al. Correlation between recent thymic emigrants and CD311 (PECAM-1) CD41 T cells in normal individuals during aging and in lymphopenic children. Eur J Immunol. 2007; 37(11):3270-3280.
31. Kohler S, Thiel A. Life after the thymus: CD311 and CD31-human naive CD41 T-cell subsets. Blood. 2009;113(4):769-774.
32. Duchrow M, Gerdes J, Schlüter C. The proliferation-Associated Ki-67 protein: definition in molecular terms. Cell Prolif. 1994;27(5):235-242.
33. Marsden VS, Strasser A. Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. Annu Rev Immunol. 2003;21:71-105.
34. Kawano Y, Kim HT, Matsuoka K, et al. Low telomerase activity in CD41 regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood. 2011;118(18):5021-5030.
35. Fink PJ. The biology of recent thymic emigrants. Annu Rev Immunol. 2013;31:31-50.
36. Thiault N, Darrigues J, Adoue V, et al. Peripheral regulatory T lymphocytes recirculating to the thymus suppress the development of their precursors. Nat Immunol. 2015;16(6):628-634.
37. Weist BM, Kurd N, Boussier J, Chan SW, Robey EA. Thymic regulatory T cell niche size is dictated by limiting IL-2 from antigen-bearing dendritic cells and feedback competition. Nat Immunol. 2015;16(6):635-641.
38. Anderson BE, McNiff J, Yan J, et al. Memory CD41 T cells do not induce graft-versus-host disease. J Clin Invest. 2003;112(1):101-108.
39. Bleakley M, Heimfeld S, Loeb KR, et al. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest. 2015;125(7):2677-2689.
40. Meyer EH, Hsu AR, Liliental J, et al. A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graftversus-host disease. Blood. 2013;121(24): 4955-4962.
41. Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versushost disease. Sci Transl Med. 2013;5(179): 179ra43.
42. Roncarolo MG, Gregori S, Lucarelli B, Ciceri F, Bacchetta R. Clinical tolerance in allogeneic hematopoietic stem cell transplantation. Immunol Rev. 2011;241(1):145-163.
43. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: Take a billion or so and call me in the morning. Immunity. 2009;30(5): 656-665.
44. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055-2066.
45. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3): 1061-1070.
46. Kennedy-Nasser AA, Ku S, Castillo-Caro P, et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014;20(8):2215-2225.
47. Parmar S, Liu X, Najjar A, et al. Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo. Blood. 2015;125(9):1502-1506.